Align Capital Partners Recapitalizes Premier Biotech
December 7, 2022
Align Capital Partners has completed a recapitalization of Premier Biotech, a Minneapolis-based provider of point-of-care drugs of abuse testing devices and accredited laboratory services. Cascadia Capital served as exclusive financial advisor; Align will partner with management to scale the business, accelerate product development and expand the company's reach across workplace, government and clinical end markets.
- Buyers
- Align Capital Partners
- Targets
- Premier Biotech
- Industry
- Medical Devices
- Location
- Minnesota, United States
- Transaction Type
- Recapitalization
Explore More
Related Acquisitions
-
Premier Biotech Acquires NexScreen and TransMed
June 19, 2026
Healthcare Services
Premier Biotech (backed by Align Capital Partners) announced the acquisitions of NexScreen and TransMed to expand its drug and alcohol testing diagnostic product portfolio and global footprint. The deals add NexScreen’s point-of-care diagnostic testing presence in Australia and New Zealand and TransMed’s drug testing product catalog, e-commerce platform, and direct customer base.
-
Premier Biotech Acquires NexScreen and TransMed
June 18, 2026
Healthcare Services
Align Capital Partners-backed Premier Biotech announced the acquisitions of NexScreen and TransMed to expand its product portfolio, e-commerce capabilities, and global footprint. NexScreen adds point-of-care diagnostic testing presence in Australia and New Zealand, while TransMed strengthens Premier’s catalog and online distribution to 1,000+ direct customer accounts.
-
Premier Biotech Acquires GH Solutions to Expand Point-of-Care Testing Presence
April 9, 2026
Healthcare Services
Align Capital Partners-backed Premier Biotech has acquired GH Solutions, a distributor of point-of-care diagnostic testing products. The deal expands Premier’s customer base and broadens the solutions GH can offer to Premier’s existing network, with focus on government and workplace customers.
-
Premier Biotech Acquires National Test Systems
November 5, 2025
Medical Devices
Premier Biotech, a portfolio company of Align Capital Partners, has acquired National Test Systems (NTS), a provider of rapid point-of-care drug screening supplies and services that serves more than 1,500 facilities across the United States. The acquisition expands Premier's point-of-care testing capabilities (including oral fluid testing) and deepens its presence in government and behavioral health end markets; NTS CEO Andrew Panico will remain involved to support the transition.
-
Prairie Capital Recapitalizes Kashi Clinical Laboratories
June 20, 2024
Healthcare Services
Prairie Capital partnered with founder Dr. Zahra Kashi and senior management to recapitalize Kashi Clinical Laboratories, a Portland, Oregon-based accredited clinical laboratory specializing in HLA typing, post-transplant monitoring, genomic sequencing and diagnostic testing. Prairie will support accelerated growth through investments in human capital, sales & marketing, technology and infrastructure, as well as pursuing add-on acquisitions.
-
Align Capital Partners Recapitalizes Cleartelligence
January 5, 2023
Data & Analytics
Align Capital Partners (ACP) completed a recapitalization of Cleartelligence, a Newton, Massachusetts–based data engineering and analytics consulting firm. The deal keeps the company’s founders and existing management as significant investors while providing capital and resources to accelerate growth, expand services and pursue strategic add‑on acquisitions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.